These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21651615)

  • 1. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.
    Upreti VV; Boulton DW; Li L; Ching A; Su H; Lacreta FP; Patel CG
    Br J Clin Pharmacol; 2011 Jul; 72(1):92-102. PubMed ID: 21651615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
    Boulton DW
    Clin Pharmacokinet; 2017 Jan; 56(1):11-24. PubMed ID: 27282159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic study of saxagliptin in healthy Chinese subjects.
    Li H; Yang L; Tou CK; Patel CG; Zhao J
    Clin Drug Investig; 2012 Jul; 32(7):465-73. PubMed ID: 22668067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
    Scheen AJ
    Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
    Noh YH; Lim HS; Jin SJ; Kim MJ; Kim YH; Sung HR; Choi HY; Bae KS
    Clin Ther; 2012 May; 34(5):1182-94. PubMed ID: 22534255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
    Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG
    Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen(®), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women.
    Upreti VV; Hsiang CB; Li L; Xu X; LaCreta FP; Boulton DW
    Diabetes Obes Metab; 2012 Dec; 14(12):1155-7. PubMed ID: 22776778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.
    Boulton DW; Smith CH; Li L; Huang J; Tang A; LaCreta FP
    Clin Drug Investig; 2011; 31(9):619-30. PubMed ID: 21819160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic Interaction Study Between Saxagliptin and Omeprazole, Famotidine, or Magnesium and Aluminum Hydroxides Plus Simethicone in Healthy Subjects: An Open-Label Randomized Crossover Study.
    Ren S; Boulton DW
    Clin Pharmacol Drug Dev; 2019 May; 8(4):549-558. PubMed ID: 30500110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
    Su H; Boulton DW; Barros A; Wang L; Cao K; Bonacorsi SJ; Iyer RA; Humphreys WG; Christopher LJ
    Drug Metab Dispos; 2012 Jul; 40(7):1345-56. PubMed ID: 22496391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic/Pharmacodynamic modelling of Saxagliptin and its active metabolite, 5-hydroxy Saxagliptin in rats with Type 2 Diabetes Mellitus.
    Wang T; Tao T; Liu Y; Dong J; Ni S; Liu Y; Li Y; Xu N; Sun Z
    BMC Pharmacol Toxicol; 2024 Jun; 25(1):35. PubMed ID: 39103956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study.
    Harrison B; Magee MH; Mandagere A; Walker G; Dufton C; Henderson LS; Boinpally R
    Clin Drug Investig; 2010; 30(12):875-885. PubMed ID: 20923245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential inhibition of sildenafil and macitentan on saxagliptin metabolism.
    Dai GX; Tan W; Shen Y; Lin D; Xu RA; Lin Q; Wei Z
    Toxicol Appl Pharmacol; 2024 May; 486():116934. PubMed ID: 38663673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
    He YL
    Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
    Fura A; Khanna A; Vyas V; Koplowitz B; Chang SY; Caporuscio C; Boulton DW; Christopher LJ; Chadwick KD; Hamann LG; Humphreys WG; Kirby M
    Drug Metab Dispos; 2009 Jun; 37(6):1164-71. PubMed ID: 19251818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically Based Pharmacokinetic Modeling Characterizes the Drug-Drug Interaction Between Saxagliptin and Rifampicin in Patients With Renal Impairment.
    Wu W; Lin R; Ke M; Ye L; Lin C
    J Clin Pharmacol; 2023 Jul; 63(7):848-858. PubMed ID: 36869593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of a Pharmacokinetic Interaction Between Saxagliptin and Dapagliflozin in Healthy Subjects: A Randomized Crossover Study.
    Vakkalagadda B; Lubin S; Reynolds L; Liang D; Marion AS; LaCreta F; Boulton DW
    Clin Ther; 2016 Aug; 38(8):1890-9. PubMed ID: 27491280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
    Golightly LK; Drayna CC; McDermott MT
    Clin Pharmacokinet; 2012 Aug; 51(8):501-14. PubMed ID: 22686547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects.
    Patel CG; Zhang J; Li L; Gooding L; Croop R; Li T; Boulton DW
    J Clin Pharmacol; 2010 Oct; 50(10):1211-6. PubMed ID: 20150522
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.